Dashboard
High Management Efficiency with a high ROE of 17.54%
Company has a low Debt to Equity ratio (avg) at 0 times
Poor long term growth as Net Sales has grown by an annual rate of 6.69% and Operating profit at -0.24% over the last 5 years
Flat results in Sep 26
Stock is technically in a Mildly Bearish range
With ROE of 17.7, it has a Attractive valuation with a 4 Price to Book Value
Falling Participation by Institutional Investors
Stock DNA
Pharmaceuticals & Biotechnology
INR 1,487 Cr (Small Cap)
22.00
40
0.94%
-0.10
17.70%
4.07
Total Returns (Price + Dividend) 
Latest dividend: 1.0043044414009 per share ex-dividend date: Nov-06-2026
Risk Adjusted Returns v/s 
Returns Beta
News

Amrutanjan Health Care Ltd is Rated Hold
Amrutanjan Health Care Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 03 Nov 2026. While the rating was revised on that date, the analysis and financial metrics discussed here reflect the stock’s current position as of 21 November 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.
Read More
Amrutanjan Health Care Ltd Technical Momentum Shifts Amid Mixed Market Signals
Amrutanjan Health Care Ltd has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend, reflecting a complex interplay of bullish and bearish signals across key technical indicators. Despite a modest day gain of 1.41%, the stock’s broader performance remains challenged, with mixed signals from MACD, RSI, moving averages, and other momentum oscillators suggesting cautious investor sentiment.
Read More
Amrutanjan Health Care Ltd Technical Momentum Shifts Amid Mixed Market Signals
Amrutanjan Health Care Ltd has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bearish stance. Despite some bullish weekly indicators, monthly signals suggest caution for investors as the stock navigates a challenging phase within the Pharmaceuticals & Biotechnology sector.
Read More Announcements 
Board Meeting Outcome for Outcome For The Unaudited Financial Results For The Quarter And Half Year Ended September 30 2026
03-Nov-2026 | Source : BSEOutcome for the Unaudited Financial Results for the Quarter and Half Year Ended September 30 2026
Record Date For The First Interim Dividend 2026-27
03-Nov-2026 | Source : BSERecord Date for the first interim dividend 2026-27
Investor Presentation For The Quarter Ended 30Th September 2026
03-Nov-2026 | Source : BSEInvestor Presentation for the Quarter Ended 30th September 2026
Corporate Actions 
No Upcoming Board Meetings
Amrutanjan Health Care Ltd has declared 100% dividend, ex-date: 06 Nov 26
Amrutanjan Health Care Ltd has announced 1:2 stock split, ex-date: 13 Apr 18
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2026
Shareholding Compare (%holding) 
Promoters
None
Held by 6 Schemes (3.6%)
Held by 32 FIIs (3.47%)
Goodhealth Holdings Private Limited (20.15%)
Isif Equity Long-short Fund (3.47%)
35.53%
Quarterly Results Snapshot (Standalone) - Sep'26 - YoY
YoY Growth in quarter ended Sep 2026 is 14.85% vs 7.08% in Sep 2025
YoY Growth in quarter ended Sep 2026 is 23.78% vs 18.31% in Sep 2025
Half Yearly Results Snapshot (Standalone) - Sep'25
Growth in half year ended Sep 2025 is 9.35% vs 9.30% in Sep 2024
Growth in half year ended Sep 2025 is 35.71% vs 18.40% in Sep 2024
Nine Monthly Results Snapshot (Standalone) - Dec'25
YoY Growth in nine months ended Dec 2025 is 11.50% vs 7.56% in Dec 2024
YoY Growth in nine months ended Dec 2025 is 16.99% vs 13.89% in Dec 2024
Annual Results Snapshot (Standalone) - Mar'26
YoY Growth in year ended Mar 2026 is 11.23% vs 7.26% in Mar 2025
YoY Growth in year ended Mar 2026 is 13.95% vs 13.03% in Mar 2025